Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The tumor vascularity and lipiodol deposition predicts risk of disease progression after TACE in patients with unresectable HCC

Date

21 Dec 2015

Session

Basic Science, biomarkers, new diagnostics and translational research

Presenters

Cheng-Shi Chen

Citation

Annals of Oncology (2015) 26 (suppl_9): 107-107. 10.1093/annonc/mdv529

Authors

C. Chen, F. Li, C. Guo, J. Xiao, H. Hu, H. Cheng, L. Zheng, D. Zong, J. Ma, L. Jiang, H. Li

Author affiliations

  • Department Of Radiology, Zhengzhou University Affiliated Cancer Hospital, 450008 - Zhengzhou/CN
More

Aim/Background

Patients with BCLC stage B HCC are currently treated with transarterial chemoembolization (TACE) which uses intra-arterial infusion of lipiodol, along with a chemotherapeutic agent to selectively obstruct tumor vessels. Lipiodol retention and tumor vascularity have been suggested as factors impacting overall survival (OS) and time to progression (TTP) in patients with unresectable HCC who receive TACE. In this study, the prognostic value of tumor vascularity and lipiodol deposition as well as other risk factors on OS and TTP were evaluated in HCC patients.

Aim/Background

Patients with BCLC stage B HCC are currently treated with transarterial chemoembolization (TACE) which uses intra-arterial infusion of lipiodol, along with a chemotherapeutic agent to selectively obstruct tumor vessels. Lipiodol retention and tumor vascularity have been suggested as factors impacting overall survival (OS) and time to progression (TTP) in patients with unresectable HCC who receive TACE. In this study, the prognostic value of tumor vascularity and lipiodol deposition as well as other risk factors on OS and TTP were evaluated in HCC patients.

Methods

HCC patients were grouped based on tumor vascularity and lipidiol deposition after TACE. Tumors were classified as hypervascular or hypovascular based on contrast enhancement on arterial phase baseline CT scans. Lipiodol deposition was evaluated using CT scans. There were 101 patients in the good blood supply group, and 73 patients in the poor lipidiol deposition group.

Methods

HCC patients were grouped based on tumor vascularity and lipidiol deposition after TACE. Tumors were classified as hypervascular or hypovascular based on contrast enhancement on arterial phase baseline CT scans. Lipiodol deposition was evaluated using CT scans. There were 101 patients in the good blood supply group, and 73 patients in the poor lipidiol deposition group.

Results

Risk of disease progression increased with increased number of nodules and increased ECOG score. The progression-free rate was significantly higher in patients with good blood supply + good lipiodol deposition compared to those with good blood supply + poor lipiodol deposition. In patients with poor lipidiol deposition, risk of death was significantly increased in BCLC stage C compared to BCLC stage B patients, while risk of death was decreased with 1) increasing number of TACE procedures and 2) with every percent increase in degree of lipidiol deposition after the first TACE. Risk of disease progression in these patients was increased with increasing tumor size, and decreased with 1) increasing number of TACE procedures and 2) every percent increase in lipidiol deposition after the first TACE.

Results

Risk of disease progression increased with increased number of nodules and increased ECOG score. The progression-free rate was significantly higher in patients with good blood supply + good lipiodol deposition compared to those with good blood supply + poor lipiodol deposition. In patients with poor lipidiol deposition, risk of death was significantly increased in BCLC stage C compared to BCLC stage B patients, while risk of death was decreased with 1) increasing number of TACE procedures and 2) with every percent increase in degree of lipidiol deposition after the first TACE. Risk of disease progression in these patients was increased with increasing tumor size, and decreased with 1) increasing number of TACE procedures and 2) every percent increase in lipidiol deposition after the first TACE.

Conclusions

Both of tumor vascularity and lipiodol deposition should be considered as predictors of disease progression after TACE. These data have important implications for the clinical management of patients with unresectable HCC. Poor lipiodol retention may predict a poor TTP and OS despite the blood supply status.

Conclusions

Both of tumor vascularity and lipiodol deposition should be considered as predictors of disease progression after TACE. These data have important implications for the clinical management of patients with unresectable HCC. Poor lipiodol retention may predict a poor TTP and OS despite the blood supply status.

Clinical trial identification

N/A

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings